[Skip to Navigation]
Sign In
Comment & Response
January 6, 2022

Use of Participation to Prevalence Ratio for Evaluating the Representation Status of Women in Oncology Clinical Trials—Reply

Author Affiliations
  • 1School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada
  • 2Department of Medicine, University of Calgary, Calgary, Alberta, Canada
  • 3Department of Hematology-Oncology, University of California, San Francisco
JAMA Oncol. 2022;8(3):480. doi:10.1001/jamaoncol.2021.6971

In Reply We appreciate the comments from Chen et al on our Research Letter evaluating the inclusion of women in global oncology drug trials over the past 20 years.1 Our central conclusion was that women were underrepresented in certain tumor types.

Chen et al argue that we ought to have adjusted our analysis1 for the participation to prevalence ratio. We agree that adjustment is needed for the number of people eligible to participate, but prevalence does not capture that. The incidence of a specific tumor indication (eg, second-line metastatic breast cancer or newly diagnosed multiple myeloma) is a better indicator of individuals eligible for frontline therapy and has been used in similar studies.2,3

Add or change institution